TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maternal Problem-Solving in Childhood Cancer
Brief Summary: The purpose of this study is to help mothers of children with cancer to cope more effectively by increasing their problem-solving skills.


Options:
A: Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Supportive Non-Directive Therapy (SNDT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Non-directive Therapy (SNDT) | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Supportive Non-directive Therapy (SNDT); Assigned to Arm(s): Supportive Non-Directive Therapy (SNDT)
B: Arm Label: Active Comparator: Internet Resources Comparison (IRC); Type: EXPERIMENTAL; Interventions: Behavioral: Internet Resources Comparison (IRC) | Arm Label: I-InTERACT; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT) | Arm Label: I-InTERACT Express; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express) | Intervention Type: BEHAVIORAL; Name: Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT); Assigned to Arm(s): I-InTERACT | Intervention Type: BEHAVIORAL; Name: Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express); Assigned to Arm(s): I-InTERACT Express | Intervention Type: BEHAVIORAL; Name: Internet Resources Comparison (IRC); Assigned to Arm(s): Active Comparator: Internet Resources Comparison (IRC)
C: Intervention Type: BEHAVIORAL; Name: Problem-Solving Skills Training; Assigned to Arm(s): N/A
D: Arm Label: Teen Online Problem Solving; Type: EXPERIMENTAL; Interventions: Behavioral: Teen Online Problem Solving | Arm Label: Internet Resources Comparison; Type: EXPERIMENTAL; Interventions: Behavioral: Teen Online Problem Solving | Intervention Type: BEHAVIORAL; Name: Teen Online Problem Solving; Assigned to Arm(s): Internet Resources Comparison, Teen Online Problem Solving

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maternal Problem-Solving in Childhood Cancer
Brief Summary: The purpose of this study is to help mothers of children with cancer to cope more effectively by increasing their problem-solving skills.


Options:
A: Intervention Type: BEHAVIORAL; Name: Problem-Solving Skills Training; Assigned to Arm(s): N/A
B: Arm Label: family diabetes management intervention; Type: EXPERIMENTAL; Interventions: Behavioral: family diabetes management intervention | Intervention Type: BEHAVIORAL; Name: family diabetes management intervention; Assigned to Arm(s): family diabetes management intervention
C: Arm Label: Multisystemic Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Multisystemic Therapy | Arm Label: Standard Medical Care (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multisystemic Therapy; Assigned to Arm(s): Multisystemic Therapy
D: Arm Label: Coaching group for lifestyle changes; Type: EXPERIMENTAL; Interventions: Behavioral: Coaching | Arm Label: Routine pediatric care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coaching; Assigned to Arm(s): Coaching group for lifestyle changes

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event
Brief Summary: The purpose of the study was to determine the long-term effect of sibutramine treatment on cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event.


Options:
A: Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Lorcaserin plus Lifestyle Modification; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorcaserin | Arm Label: Placebo plus Lifestyle Modification; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lorcaserin; Assigned to Arm(s): Lorcaserin plus Lifestyle Modification | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus Lifestyle Modification
C: Arm Label: Rimonabant; Type: EXPERIMENTAL; Interventions: Drug: Rimonabant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Rimonabant) | Intervention Type: DRUG; Name: Rimonabant; Assigned to Arm(s): Rimonabant | Intervention Type: DRUG; Name: Placebo (for Rimonabant); Assigned to Arm(s): Placebo
D: Arm Label: Sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lead-in sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Sibutramine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Lead-in sibutramine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event
Brief Summary: The purpose of the study was to determine the long-term effect of sibutramine treatment on cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event.


Options:
A: Arm Label: caffeine and ephedrine; Type: EXPERIMENTAL; Interventions: Drug: caffeine and ephedrine | Arm Label: leptin A; Type: EXPERIMENTAL; Interventions: Drug: Leptin A | Arm Label: caffeine, ephedrine, and leptin A; Type: EXPERIMENTAL; Interventions: Drug: caffeine, ephedrine, and leptin A | Intervention Type: DRUG; Name: caffeine and ephedrine; Assigned to Arm(s): caffeine and ephedrine | Intervention Type: DRUG; Name: Leptin A; Assigned to Arm(s): leptin A | Intervention Type: DRUG; Name: caffeine, ephedrine, and leptin A; Assigned to Arm(s): caffeine, ephedrine, and leptin A
B: Arm Label: Glucosanol; Type: ACTIVE_COMPARATOR; Interventions: Device: Glucosanol | Intervention Type: DEVICE; Name: Glucosanol; Assigned to Arm(s): Glucosanol
C: Intervention Type: DRUG; Name: glucophage XR; Assigned to Arm(s): N/A
D: Arm Label: Sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lead-in sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Sibutramine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Lead-in sibutramine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT)
Brief Summary: The BENEDICT study is conducted to examine the effects of an ACE inhibitor, calcium channel blockade, a combination of these, and placebo, in the prevention of micro- and macro-albuminuria in Type 2 diabetic patients.


Options:
A: Arm Label: A-1, B-1; Type: ACTIVE_COMPARATOR; Interventions: Drug: trandolapril | Arm Label: A-2, B-2; Type: ACTIVE_COMPARATOR; Interventions: Drug: trandolapril/verapamil | Arm Label: A-3; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: A-4; Type: ACTIVE_COMPARATOR; Interventions: Drug: verapamil | Intervention Type: DRUG; Name: trandolapril; Assigned to Arm(s): A-1, B-1 | Intervention Type: DRUG; Name: trandolapril/verapamil; Assigned to Arm(s): A-2, B-2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A-3 | Intervention Type: DRUG; Name: verapamil; Assigned to Arm(s): A-4
B: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Delapril, Delapril-Manidipine Fixed combination; Assigned to Arm(s): N/A
D: Arm Label: Benazepril/amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Drug: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Drug: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter | Arm Label: Benazepril/hydrochlorothiazide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Drug: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Drug: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter | Intervention Type: DRUG; Name: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1; Assigned to Arm(s): Benazepril/hydrochlorothiazide | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2; Assigned to Arm(s): Benazepril/hydrochlorothiazide | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Assigned to Arm(s): Benazepril/hydrochlorothiazide

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT)
Brief Summary: The BENEDICT study is conducted to examine the effects of an ACE inhibitor, calcium channel blockade, a combination of these, and placebo, in the prevention of micro- and macro-albuminuria in Type 2 diabetic patients.


Options:
A: Arm Label: A-1, B-1; Type: ACTIVE_COMPARATOR; Interventions: Drug: trandolapril | Arm Label: A-2, B-2; Type: ACTIVE_COMPARATOR; Interventions: Drug: trandolapril/verapamil | Arm Label: A-3; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: A-4; Type: ACTIVE_COMPARATOR; Interventions: Drug: verapamil | Intervention Type: DRUG; Name: trandolapril; Assigned to Arm(s): A-1, B-1 | Intervention Type: DRUG; Name: trandolapril/verapamil; Assigned to Arm(s): A-2, B-2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A-3 | Intervention Type: DRUG; Name: verapamil; Assigned to Arm(s): A-4
B: Arm Label: Aliskiren + Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine, Drug: hydrochlorothiazide, Drug: Aliskiren | Arm Label: Aliskiren Start - Amlodipine Add-On; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine, Drug: hydrochlorothiazide, Drug: Aliskiren | Arm Label: Amlodipine Start- Aliskiren Add-On; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine, Drug: hydrochlorothiazide, Drug: Aliskiren | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Aliskiren + Amlodipine, Aliskiren Start - Amlodipine Add-On, Amlodipine Start- Aliskiren Add-On | Intervention Type: DRUG; Name: hydrochlorothiazide; Assigned to Arm(s): Aliskiren + Amlodipine, Aliskiren Start - Amlodipine Add-On, Amlodipine Start- Aliskiren Add-On | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren + Amlodipine, Aliskiren Start - Amlodipine Add-On, Amlodipine Start- Aliskiren Add-On
C: Intervention Type: DRUG; Name: Delapril, Delapril-Manidipine Fixed combination; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT)
Brief Summary: The BENEDICT study is conducted to examine the effects of an ACE inhibitor, calcium channel blockade, a combination of these, and placebo, in the prevention of micro- and macro-albuminuria in Type 2 diabetic patients.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2
B: Arm Label: A-1, B-1; Type: ACTIVE_COMPARATOR; Interventions: Drug: trandolapril | Arm Label: A-2, B-2; Type: ACTIVE_COMPARATOR; Interventions: Drug: trandolapril/verapamil | Arm Label: A-3; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: A-4; Type: ACTIVE_COMPARATOR; Interventions: Drug: verapamil | Intervention Type: DRUG; Name: trandolapril; Assigned to Arm(s): A-1, B-1 | Intervention Type: DRUG; Name: trandolapril/verapamil; Assigned to Arm(s): A-2, B-2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): A-3 | Intervention Type: DRUG; Name: verapamil; Assigned to Arm(s): A-4
C: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
D: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The CORP 2 Trial: COlchicine for Recurrent Pericarditis.
Brief Summary: The purpose of the study is to determine whether colchicine is safe and effective in treatment and prevention of recurrent pericarditis after failure of conventional treatment.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Colchicine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colchicine | Intervention Type: DRUG; Name: Colchicine; Assigned to Arm(s): Colchicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Colchicine; Type: EXPERIMENTAL; Interventions: Drug: Colchicine (for 6 months) | Intervention Type: DRUG; Name: Colchicine (for 6 months); Assigned to Arm(s): Colchicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Colchicine; Type: EXPERIMENTAL; Interventions: Drug: Colchicine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Colchicine; Assigned to Arm(s): Colchicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Colchicine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colchicine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Colchicine; Assigned to Arm(s): Colchicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adalimumab in Early Axial Spondyloarthritis (Without Radiological Sacroiliitis): Placebo Controlled Phase Over 3 Months Followed by a 9 Months Open Extension Phase
Brief Summary: Reduction of signs and symptoms in patients with moderate to severely early axial spondyloarthritis (without radiological sacroiliitis) who have had an inadequate response to or do not tolerate NSAID therapy.

Study Objectives:Efficacy -To assess whether patients with moderate to severely active early axial spondyloarthritis (without radiological sacroiliitis) will show response when adalimumab is added to the pre-existing or in case of intolerance to NSAID therapy. Response will be measured at week 12 by change of efficacy parameters compared to baseline.Safety - To demonstrate the safety of adalimumab in study patients with moderate to severely active early axial spondyloarthritis (without radiological sacroiliitis) in patients who have had an inadequate response to or do not tolerate NSAID therapy.


Options:
A: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Adalimumab 40 mg sc every other week; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1
D: Arm Label: MabThera/Rituxan; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: rituximab [MabThera/Rituxan] | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): MabThera/Rituxan | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): MabThera/Rituxan

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adalimumab in Early Axial Spondyloarthritis (Without Radiological Sacroiliitis): Placebo Controlled Phase Over 3 Months Followed by a 9 Months Open Extension Phase
Brief Summary: Reduction of signs and symptoms in patients with moderate to severely early axial spondyloarthritis (without radiological sacroiliitis) who have had an inadequate response to or do not tolerate NSAID therapy.

Study Objectives:Efficacy -To assess whether patients with moderate to severely active early axial spondyloarthritis (without radiological sacroiliitis) will show response when adalimumab is added to the pre-existing or in case of intolerance to NSAID therapy. Response will be measured at week 12 by change of efficacy parameters compared to baseline.Safety - To demonstrate the safety of adalimumab in study patients with moderate to severely active early axial spondyloarthritis (without radiological sacroiliitis) in patients who have had an inadequate response to or do not tolerate NSAID therapy.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulphasalazine (SSZ) | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: sulphasalazine (SSZ); Assigned to Arm(s): B
B: Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Adalimumab 40 mg sc every other week; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Plasma Transfusion in Liver Transplantation : a Randomized, Double Blind, Multicenter Trial of Methylene Blue, Solvent/Detergent and Quarantined Plasma.
Brief Summary: The aim of the study is to compare the clinical efficacy of three types of plasma secured on the viral level either by quarantine or by chemical treatment in patients undergoing liver transplantation.


Options:
A: Arm Label: 1:1:1 Blood Transfusion Ratio; Type: ACTIVE_COMPARATOR; Interventions: Biological: 1:1:1 Blood Transfusion Ratio | Arm Label: 1:1:2 Blood Transfusion Ratio; Type: ACTIVE_COMPARATOR; Interventions: Biological: 1:1:2 Blood Transfusion Ratio | Intervention Type: BIOLOGICAL; Name: 1:1:1 Blood Transfusion Ratio; Assigned to Arm(s): 1:1:1 Blood Transfusion Ratio | Intervention Type: BIOLOGICAL; Name: 1:1:2 Blood Transfusion Ratio; Assigned to Arm(s): 1:1:2 Blood Transfusion Ratio
B: Intervention Type: PROCEDURE; Name: central venous catheter application; Assigned to Arm(s): N/A
C: Arm Label: No FFP transfusion prior to intervention; Type: EXPERIMENTAL; Interventions: Other: omitting FFP transfusion before an intervention | Arm Label: FFP transfusion prior to intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: omitting FFP transfusion before an intervention; Assigned to Arm(s): No FFP transfusion prior to intervention
D: Arm Label: Quarantined FFP; Type: ACTIVE_COMPARATOR; Interventions: Other: plasma | Arm Label: Methylene blue FFP; Type: ACTIVE_COMPARATOR; Interventions: Other: plasma | Arm Label: Solvent detergent FFP; Type: ACTIVE_COMPARATOR; Interventions: Other: plasma | Intervention Type: OTHER; Name: plasma; Assigned to Arm(s): Methylene blue FFP, Quarantined FFP, Solvent detergent FFP

Answer: D